Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Penn State Cancer Institute, Dana-Farber Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, National Cancer Institute, Emory University, Winship Cancer Institute, The University of Texas Southwestern Medical Center
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2587797478